Efficacy and safety of lenvatinib in combination with everolimus in metastatic renal cell carcinoma resistant to antiangiogenic targeted therapy: Russian multicenter observational study ROSLERCM.

Maria Volkova,Ahmed Abdelgafur,Zurab Amoev,Magomed Aivazov,Ksenia Gennadievna Babina,Pavel Borisov,Irina Evstigneeva,Olga Igorevna Samuseva,Alexei Kalpynsky,Elena Karabina,Natalia Kirdakova,Evgeniya Kuzmina,Latipova Dh,Elena G. Ovchinnikova,Anna Sergeevna Olshanskaya,Svetlana Protsenko,Tatiana Semiglazova,Roman Smirnov,Evgeny Usynin,Irina Chernyakova,Roslercm

Efficacy and safety of lenvatinib in combination with everolimus in metastatic renal cell carcinoma resistant to antiangiogenic targeted therapy: Russian multicenter observational study ROSLERCM.

2020

644Background: an assessment of efficacy and safety of lenvatinib in combination with everolimus in unselected patients with metastatic renal cell carcinoma (mRCC) progressed during or following ≥1...

Keywords:

Oncology
Pathology
Observational study
Targeted therapy
Lenvatinib
Renal cell carcinoma
Everolimus
Medicine
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations